<DOC>
	<DOCNO>NCT02294305</DOCNO>
	<brief_summary>This placebo-controlled study design determine efficacy , safety , tolerability vortioxetine treatment adult Major Depressive Disorder ( MDD ) comorbid Social Anxiety Disorder ( SAD ) . Half subject randomize receive vortioxetine half receive placebo .</brief_summary>
	<brief_title>Vortioxetine Versus Placebo Major Depressive Disorder Comorbid With Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . Male female adult 18 70 year age ( inclusive ) . 2 . Subjects must give write informed consent prior study procedure 3 . Diagnosis Major Depressive Disorder ( MDD ) , single episode ( 296.2 ) recurrent ( 296.3 ) , accord Diagnostic Statistical Manual Mental Disorders , version 5 ( DSM5 ) criterion , determine psychiatric evaluation investigator confirm MiniInternational Neuropsychiatric Interview ( MINI ) . 4 . Duration current Major Depressive Episode must least 4 week . 5 . Diagnosis Social Anxiety Disorder ( SAD ) ( 300.23 Social Phobia ) accord DSM5 criterion , determine psychiatric evaluation Investigator confirm MINI . 6 . Duration current SAD must least 6 month , SAD observable subject ' life suffer MDD , period occur . 7 . Subjects must minimum total score 60 Liebowitz Social Anxiety Scale ( LSAS ) Screening Baseline visit . 8 . Subjects must minimum total Montgomery Asberg Depression Rating Scale ( MADRS ) score 20 Screening Baseline visit . 9 . Subjects must Clinical Global Inventory ( CGI ) Severity score 4 great Screening Baseline visit , CGI base composite MDD SAD . 10 . Male female subject childbearing potential must commit effective form contraception duration trial ( Screening/Visit 1 FollowUp/Visit 10 ) . Effective form contraception include : condom spermicide , diaphragm spermicide , hormonal contraceptive agent ( oral , transdermal , injectable ) , implantable contraceptive device . True abstinence also consider effective form contraception . 1 . Subjects lifetime history bipolar disorder , schizophrenia , schizoaffective disorder , Obsessive Compulsive Disorder , eat disorder , body dysmorphic disorder . Subjects comorbid Generalized Anxiety Disorder , dysthymia , specific phobia include study provide MDD SAD consider primary clinical condition term need treatment . 2 . Subjects substance abuse , panic disorder , PostTraumatic Stress Disorder , past 6 month screen . 3 . Subjects start psychotherapy SAD MDD electroconvulsive therapy ( ECT ) past 6 month screen . Subjects receive psychotherapy Cognitive Behavioral Therapy 24 week prior Baseline visit eligible provide therapy continue frequency duration trial . 4 . Subjects currently pregnant lactate , childbearing potential able willing practice effective method contraception ( outline Inclusion criterion # 10 ) duration trial ( Screening/Visit 1 FollowUp/Visit 10 . 5 . Subjects , opinion investigator , clinically significant risk suicide . This would include prominent suicidal ideation suicidal behavior past 6 month screen . 6 . Systolic blood pressure ≥165 and/or diastolic blood pressure ≥95 , measure Screening Baseline visit . 7 . Positive Urine Drug Screen Screening visit , unless due prescribe medication . 8 . Any current unstable and/or clinically significant medical condition , base history evidence screen laboratory electrocardiogram ( ECG ) assessment . 9 . Subjects history complication cancer malignant tumor remission least 5 year . Basal cell skin cancer exclusionary . 10 . Subjects receive fluoxetine within 28 day Baseline visit . 11 . Subjects receive Monoamine oxidase inhibitor ( MAOIs ) within 14 day Baseline visit . 12 . Subjects receive psychotropic medication ( include selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , benzodiazepine ) within 14 day Baseline visit . Zolpidem ( Ambien ) PRN allow insomnia take 3 time per week duration trial . 13 . Treatment refractory SAD : subject history two fail treatment trial FDAapproved SAD treatment , give least 6 week , subject receive adequate dosage 14 . Treatment refractory MDD : subject history two fail treatment trial FDAapproved MDD treatment current episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Social Anxiety</keyword>
	<keyword>Social Phobia</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Vortioxetine</keyword>
</DOC>